• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Lubiprostone     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : umbel-rc:DrugProduct, within Data Space : dbpedia.org associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatMolecularFormulasyago:Abstraction100002137yago:Acid114607521yago:Agent114778436yago:Alcohol107884567yago:Beverage107881800yago:CarboxylicAcid114739360yago:CausalAgent100007347yago:Chemical114806838yago:Communication100033020yago:Compound114818238yago:Drug103247620yago:DrugOfAbuse103248958yago:FattyAcid114740227yago:Fluid114939900yago:Food100021265yago:Formula106816935yago:Ketone114926294yago:Liquid114940386yago:Material114580897yago:Matter100020827yago:Message106598915yago:MolecularFormula106817173yago:OrganicCompound114727670yago:Part113809207yago:PhysicalEntity100001930yago:Relation100031921yago:WikicatKetonesdrugyago:Statement106722453yago:Substance100019613yago:Substance100020090yago:WikicatAlcoholsyago:WikicatFattyAcidsumbel-rc:DrugProduct New Facet based on Instances of this Class

Lubiprostone (rINN, marketed under the trade name Amitiza among others) is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company. The cost to the NHS was £29.68 per 24 mcg 28-cap pack as of April 2017. The drug is available in the United States, Japan, Switzerland, India, Bangladesh, United Kingdom, and Canada.